Chapdelaine AG - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells.

Ku GC, Chapdelaine AG, Ayrapetov MK, Sun G. Ku GC, et al. Among authors: chapdelaine ag. Cancers (Basel). 2022 Aug 20;14(16):4027. doi: 10.3390/cancers14164027. Cancers (Basel). 2022. PMID: 36011019 Free PMC article.

Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer.

Chapdelaine AG, Sun G. Chapdelaine AG, et al. Biomolecules. 2023 Aug 1;13(8):1207. doi: 10.3390/biom13081207. Biomolecules. 2023. PMID: 37627272 Free PMC article. Review.

Molecular Pharmacology of Dasatinib Provides Unique Insights into the Mechanistic Basis of Success and Failure of Targeted Cancer Therapy.

Chapdelaine AG, Sun G. Chapdelaine AG, et al. ACS Pharmacol Transl Sci. 2024 Dec 6;8(1):1-9. doi: 10.1021/acsptsci.4c00492. eCollection 2025 Jan 10. ACS Pharmacol Transl Sci. 2024. PMID: 39816794 Review.

The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells.

Chapdelaine AG, Ku GC, Sun G, Ayrapetov MK. Chapdelaine AG, et al. Cancers (Basel). 2023 Dec 12;15(24):5805. doi: 10.3390/cancers15245805. Cancers (Basel). 2023. PMID: 38136350 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4 results

Search Page

Filters